Alzheimer Disease
Conditions
Brief summary
Diseases of dementia are chronic, untreatable, and cause a massive burden of morbidity. In this proposal, we seek to tackle the problem of better, earlier, and more efficient diagnosis using deuterium metabolic imaging (DMI). The study is divided in two sub-studies: 1) optimization and simplification of DMI protocols, and 2) a cross-sectional study of DMI in Alzheimer's patients and healthy controls.
Interventions
DIAGNOSTIC_TESTDeuterium metabolic imaging
MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
Sponsors
Aarhus University Hospital
University of Aarhus
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Inclusion criteria
AD-patients: * Aged 55-85 years. * Male or female. * AD diagnosis by the NIA-AA 2011 research criteria.8 * Able to give written informed consent. * Mini-mental state examination (MMSE) equal to or above 18.9 * Brain FDG-PET performed at Aarhus University Hospital consistent with AD. Healthy participants: * Aged 18-85 years. * Male or female.
Exclusion criteria
All participants: * Diabetes or any other metabolic disease. * Other significant brain disease: * Strokes. * Tumors. * Chronic small vessel disease (clinically suspected, or Fazekas ≥ 2 if clinical MRI is available). * Epilepsy. * Other neurodegenerative or -inflammatory disease. * Contraindications for MRI: * Pacemaker, neurostimulator or cochlear implant. * Metal foreign bodies such as fragments and irremovable piercings. * Unsafe medical implants (safety of heart valves, hips and the like must be confirmed). * Claustrophobia. * Largest circumference including arms \> 160 cm. * Pregnant - women must be post-menopausal or confirmed non-pregnant by an onsite test.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Deuterium Metabolic Imaging | Up to 150 mins after 2H-glucose ingestion | Glucose concentration in whole-brain referenced to baseline scan (sub-study 1). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Deuterium Metabolic Imaging | Up to 150 mins after 2H-glucose ingestion | Simpler DMI quantifications, including reference to external phantoms and internal reference, in the same regions defined in primary outcomes. |
| Blood samples | Up to 150 mins after 2H-glucose ingestion | Glucose |
| FDG-PET from the records (sub study 2) | At time of Deuterium Metabolic Imaging | Brain glucose uptake |
| Cognitive tests from the records (sub study 2) | At time of Deuterium Metabolic Imaging | The Mini-Mental State Exam (0-30, 30 is best) |
| Cerebrospinal fluid biochemistry from the records (sub study 2) | At time of Deuterium Metabolic Imaging | Total tau protein |
Countries
Denmark
Outcome results
None listed